 Glenson Samuel, MD
| Title | Faculty Physician, Division of Hematology/Oncology/BMT |
|---|
| Institution | Children's Mercy Kansas City |
|---|
| Department | Pediatrics |
|---|
| Address | 2401 Gilham Rd
Kansas City MO 64108
|
|---|
ORCID
.gif) | 0000-0003-0344-278X  |
|---|
| vCard | Download vCard |
|---|
|
|
|
| Title | Assistant Professor of Pediatrics |
|---|
| Institution | University of Missouri-Kansas City |
|---|
| Department | Pediatrics |
|---|
|
|---|
| Title | Clinical Assistant Professor of Pediatrics |
|---|
| Institution | University of Kansas Medical Center |
|---|
| Department | Pediatrics |
|---|
|
|---|
|
 Biography | Sri Ramachandra Medical College and Research Institute, Chennai, India | MD | 2005 | | | Southern Illinois University School of Medicine, Springfield, IL | Residency | 2010 | Pediatrics | | Children's Mercy Hospital and Clinics, Kansas City, MO | Fellowship | 2014 | Hematology/Oncology |
Overview Research Dr. Samuel's laboratory focus is currently in the field of pediatric sarcoma translational research; the main emphasis is in potential biomarkers related to Ewing Sarcoma derived exosomes in the pediatric population. Other ongoing collaborative research is on novel therapeutics for refractory or recurrent Ewing Sarcoma and Osteosarcoma patients.
(SAMUEL, GLENSON)Jul 1, 2014 - Jun 30, 2017 Alex's Lemonade Stand Young Investigator
Exosomes as Biomarkers to Monitor Disease Progression and Response to Therapy in Ewing Sarcoma
Role Description: For the first time to characterize exosomes released from Ewing sarcoma tumor cells and to study their unique contents in order to develop a biomarker for tumor presence/recurrence and response to treatment.
Role: Principal Investigator |
| (SAMUEL, GLENSON)Aug 1, 2016 Noah’s Bandage Project Foundation
Exosomes as biomarkers of disease and therapy-resistance in Ewing Sarcoma
Role Description: Characterize and Identify predictive exosome-based microRNA biomarkers of chemoresistance and disease recurrence for Ewing sarcoma.
Role: Principal Investigator |
| (SAMUEL, GLENSON)Sep 1, 2016 - Aug 31, 2018 Braden's Hope Foundation Cancer Research Program
Exosome miRNAs as biomarkers and targets for chemoresistance in Ewing Sarcoma
Role Description: exploitation of Ewing Sarcoma tumor derived exosomal microRNAs (miRNAs) in order to provide a simple and cost effective “liquid biopsy” and the identification of potential therapeutic targets to combat chemoresistance based on these exosomal microRNA biomarkers.
Role: Co-Principal Investigator |
| R33CA214333 (ZENG, YONG)May 10, 2017 - Apr 30, 2020 NIH
Integrated exosomes profiling for minimally invasive diagnosis and monitoring of cancer
Role: Co-Investigator |
| (SAMUEL, GLENSON)Nov 6, 2017 Noah’s Bandage Project Foundation
Identifying novel kinesin inhibitors for the therapeutic management of recurrent and/or progressive pediatric Ewing Sarcoma and Osteosarcoma
Role Description: Discovery and validation of combination kinesin motor protein inhibitors both in vitro and in vivo for the purpose of use in pediatric patients with recurrent or progressive (refractory) Ewing Sarcoma and Osteosarcoma
Role: Co-Principal Investigator |
| (SAMUEL, GLENSON)Dec 31, 2019 - Sep 30, 2021 Hyundai Hope on Wheels Young Investigator
Exosomal microRNAs to enhance chemosensitivity and advance precision medicine in pediatric Ewing Sarcoma
Role Description: Identify and design therapeutically relevant miRNA mimic or trap payloads to enhance chemotherapy sensitivity in Ewing Sarcoma cells. Combination of bioinformatic tools and in vitro assays will be used to refine 63 previously identified miRNAs and isolate specific miRNAs which may impact chemosensitivity within a panel of 8 Ewing Sarcoma cell lines. Engineer exosomes to deliver therapeutically relevant miRNA mimic or trap payloads to EWS cells and tumors. |
Bibliography
-
Samuel G, Crow J, Klein JB, Merchant ML, Nissen E, Koestler DC, Laurence K, Liang X, Neville K, Staggs V, Ahmed A, Atay S, Godwin AK. Ewing sarcoma family of tumors-derived small extracellular vesicle proteomics identify potential clinical biomarkers. Oncotarget. 2020 Aug 04; 11(31):2995-3012. PMID: 32821345.
-
Crow J, Samuel G, Godwin AK. Beyond tumor mutational burden: potential and limitations in using exosomes to predict response to immunotherapy. Expert Rev Mol Diagn. 2019 12; 19(12):1079-1088. PMID: 31687863.
-
Ma Y, Baltezor M, Rajewski L, Crow J, Samuel G, Staggs VS, Chastain KM, Toretsky JA, Weir SJ, Godwin AK. Targeted inhibition of histone deacetylase leads to suppression of Ewing sarcoma tumor growth through an unappreciated EWS-FLI1/HDAC3/HSP90 signaling axis. J Mol Med (Berl). 2019 07; 97(7):957-972. PMID: 31025088.
-
Zhang P, Crow J, Lella D, Zhou X, Samuel G, Godwin AK, Zeng Y. Ultrasensitive quantification of tumor mRNAs in extracellular vesicles with an integrated microfluidic digital analysis chip. Lab Chip. 2018 12 04; 18(24):3790-3801. PMID: 30474100.
-
Zhang P, Samuel G, Crow J, Godwin AK, Zeng Y. Molecular assessment of circulating exosomes toward liquid biopsy diagnosis of Ewing sarcoma family of tumors. Transl Res. 2018 11; 201:136-153. PMID: 30031766.
This graph shows the total number of publications by year, by first, middle/unknown, or last author.
To see the data from this visualization as text, click here.
| Year | Publications |
|---|
| 2018 | 2 | | 2019 | 2 | | 2020 | 1 |
To return to the timeline, click here.
|
Click the "See All" links for more information and interactive visualizations!
Concepts Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|